Table 5. Studies correlating neoadjuvant chemoradiation and anastomotic leak.
| Study | PSM/RCT | N | NCR regimen | NCR leak (%) | Upfront leak (%) | p |
|---|---|---|---|---|---|---|
| Reynolds [2006] | Non-PSM | 200 | Cisplatin/5-FU 40–50 Gy | 6.0 | 2.0 | 0.26 |
| CALGB 9781 [2008] | RCT | 48 | Cisplatin/5-FU 50.4 Gy | 8.0 | 0 | NS |
| Merritt [2011] | Non-PSM | 138 | Platinum doublet 40–60 Gy | 14.8 | 10.7 | 0.45 |
| CROSS [2012] | RCT | 366 | Carboplatin/taxol 41.4 Gy | 22.0 | 30.0 | NS |
| Markar [2013] | Non-PSM | 340 | Cisplatin/5-FU 50.4 Gy | 2.9 | 4.6 | 0.51 |
| Bosch [2014] | PSM | 326 | Carboplatin/taxol 41.4 Gy | 11.5 | 13.5 | 0.63 |
| Gronnier [2014] | Non-PSM | 2,080 | Cisplatin/5-FU 45 Gy | 8.8 | 10.6 | 0.22 |
| PSM | 1,086 | 8.8 | 11.0 | 0.23 | ||
| Current study | Non-PSM | 820 | Cisplatin/5-FU or carboplatin/taxol 45–59.4 Gy | 4.1 | 8.0 | 0.04 |
| PSM | 518 | 4.2 | 7.7 | 0.12 |
PSM, propensity score matched; RCT, randomized controlled trial; NCR, neoadjuvant chemoradiation; 5-FU, 5-fluorouracil; Gy, Gray.